» Articles » PMID: 12167688

What is Cystic Fibrosis?

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2002 Aug 9
PMID 12167688
Citations 50
Authors
Affiliations
Soon will be listed here.
Citing Articles

A guide to virulence capabilities, as we currently understand them.

Bhaumik R, Aungkur N, Anderson G Front Cell Infect Microbiol. 2024; 13:1322853.

PMID: 38274738 PMC: 10808757. DOI: 10.3389/fcimb.2023.1322853.


Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor.

Li H, Rodrat M, Al-Salmani M, Veselu D, Han S, Raraigh K J Physiol. 2024; 602(2):333-354.

PMID: 38186087 PMC: 10872379. DOI: 10.1113/JP285727.


Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.

Martin C, Guzior D, Gonzalez C, Okros M, Mielke J, Padillo L Respir Res. 2023; 24(1):317.

PMID: 38104128 PMC: 10725582. DOI: 10.1186/s12931-023-02630-z.


Epithelial Transport in Disease: An Overview of Pathophysiology and Treatment.

Clemente-Suarez V, Martin-Rodriguez A, Redondo-Florez L, Villanueva-Tobaldo C, Yanez-Sepulveda R, Tornero-Aguilera J Cells. 2023; 12(20).

PMID: 37887299 PMC: 10605148. DOI: 10.3390/cells12202455.


Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.

Martin C, Guzior D, Gonzalez C, Okros M, Mielke J, Padillo L Res Sq. 2023; .

PMID: 37841851 PMC: 10571617. DOI: 10.21203/rs.3.rs-3356170/v1.